Tablet compression campaigns built around Wuwei Changqing Granules as the bulk active ingredient typically begin with incoming particle-size classification on a vibratory sieve stack according to USP <786>, because the granule fraction retained between 150 µm and 850 µm dominates die-fill consistency and final tablet weight variability. Production-scale observations on a 45-station rotary tablet press show that when the sub-150 µm fines fraction exceeds 20% w/w, tablet weight RSD drifts above 2.0%, while an excess of granules above 850 µm produces visible punch sticking and higher friability. Incoming lots are therefore pre-blended with a lactose monohydrate and microcrystalline cellulose carrier and, when necessary, passed through a cone mill with a 1.0 mm rasp screen at 1,200 rpm to normalize the particle-size distribution before weighing.

When a finished scored tablet is targeted at 50 mg active per 400 mg tablet and the API granule assay is 85.0 wt% with 2.5% w/w loss on drying, the corrected input mass is 58.8 mg per tablet, or 14.7 wt% of the total compression blend. If the same granule lot assays at 75.0 wt%, the input increases to 73.3 mg per tablet, or 18.3 wt%. This arithmetic adjustment is performed at dispensing and verified by in-process blend assay before compression; the acceptance window for active content in the final blend is 95.0–105.0% of label claim under the registration dossier. The balance of the formulation is blended in a 1,200 L bin blender at 10 rpm for 15 min; magnesium stearate is added only during the final 3 min to prevent over-lubrication and dissolution slowdown. Compression is run on a rotary tablet press with 8–14 kN main compression force and 3–5 kN precompression, producing tablets with breaking force 60–90 N measured by USP <1217> and friability below 1.0% w/w by USP <1216>. Disintegration time in 900 mL of water at 37 ± 2 °C is maintained below 15 min; dissolution testing follows USP <711> Apparatus II at 50 rpm in pH 6.8 phosphate buffer, with a typical acceptance of not less than 75% released at 45 min.

Compliance for this solid oral dosage form is anchored to USP <905> or Ph. Eur. 2.9.40 for uniformity of dosage units, 21 CFR 211.166 for blend and tablet assay sampling, and VICH GL1 for process validation of the dry-blend step. Terminal product types produced through this route are multipurpose scored tablets, palatable chewable tablets for companion animals, and large veterinary bolus tablets for cattle and equine administration.

What limits sterile filterability when Wuwei Changqing Granules are reconstituted for injectable solutions?

Sterile solution manufacture from the supplied granule matrix is governed less by active content than by the dispersibility and dissolution kinetics of the granule excipients in Water for Injection. Because the granules are designed for solid-dose flow, the particle-size reduction step must produce a D90 below 60 µm before extraction; otherwise, residual particles above that threshold raise the pressure differential during sterilizing-grade filtration and shorten 0.22 µm membrane service life. The extraction vessel is jacketed at 40 ± 5 °C under nitrogen sparging to limit oxidative degradation of the marker compound; the processing window is deliberately narrow because a temperature above 45 °C accelerates hydrolytic impurity formation in stability trials, while a temperature below 35 °C reduces extraction efficiency below 90% after 30 min. Published data for this specific configuration is limited, so the extraction time and temperature window must be confirmed by forced degradation and pilot-scale filterability runs before commercial batch execution.

To prepare a 5.0 mg/mL active injectable solution in a 100 mL vial, a granule lot assayed at 90.0 wt% active with 2.0% w/w moisture requires 5.56 g/L on an anhydrous basis and 5.67 g/L as-is. The bulk solution is assayed by HPLC and adjusted with Water for Injection to the final target concentration; overage must be justified by stability data and the maximum assay upper limit of 105.0% label claim. After extraction, the solution is cooled to 20–25 °C and pH-adjusted to 5.5–6.5 with 0.1 N hydrochloric acid or sodium hydroxide. A two-stage filtration train of 0.45 µm polyethersulfone prefilter and sterilizing-grade 0.22 µm polyethersulfone final filter is used; filter integrity is tested by bubble point and diffusion per ASTM F838-20 before and after filtration. Terminal sterilization by autoclaving at 121 °C for 15 min is applied only if the formulation shows no assay loss greater than 2.0% and no single impurity above 0.5% in thermal challenge studies; otherwise aseptic filtration and filling in a Grade A zone under EU GMP Annex 1 is required.

Sterility is assessed by USP <71>, bacterial endotoxins by USP <85> with a limit established in the registration dossier, and particulate matter by USP <788>. Residual solvent control follows VICH GL18 and ICH Q3C. Terminal products are sterile single-dose ampoules and multi-dose vials for veterinary professional administration, packaged with tamper-evident seals.

Low-dose hard capsule lines running Wuwei Changqing Granules face a segregation risk that differs from tablet work because the granule-to-diluent density mismatch is amplified in dosator-type filling heads. If the 150–850 µm granule fraction is not tightly controlled, the active content per capsule can drift outside the acceptance window without a corresponding shift in fill weight. Incoming granule bulk density measured by USP <616> is therefore tracked against a qualified range of 0.45–0.62 g/mL; lots outside this range are either reclassified for wet granulation or adjusted with densified carriers before encapsulation. Granulation size is normalized by screening through a 500 µm stainless-steel sieve, and the blend is mixed in a 600 L bin blender at 10 rpm for 12 min. An electrostatic audit is performed at 45–55% RH because surface conductivity of the granule matrix changes with moisture uptake; processing areas above 55% RH typically require pre-drying of the granules at 40 °C for 2 h to restore flow.

For a hard capsule with 25 mg active and total fill weight 250 mg, an API granule assay of 85.0 wt% requires 29.4 mg of granules per capsule, equivalent to 11.8 wt% of the encapsulation blend. At a granule assay of 78.0 wt%, the input rises to 33.3 mg, or 13.3 wt%. The final blend is sampled at the beginning, middle, and end of the encapsulation run; the active content RSD must remain below 3.0% before content uniformity testing can be expected to pass USP <905> or Ph. Eur. 2.9.40. Dosator filling pins are set to achieve a fill weight RSD below 1.5%; in-process weight checks are taken every 30 min on a 10-capsule composite. Release testing includes USP <711> dissolution in 900 mL of pH 6.8 buffer with a 75% release threshold at 45 min, USP <61>/<62> microbial limits for nonsterile products, and VICH GL3 stability to justify the selected capsule shell. Terminal products are hard gelatin and hypromellose capsules in blister packs or HDPE bottles for companion animal dispensing.

Drinking Water Soluble Powder Homogeneity and Dosage Proportionality

Water-soluble powders produced from the API granules are distributed through proportional dosing pumps in poultry and swine barns, so the manufacturing objective is particle-level uniformity of the active in a free-flowing, rapidly dispersible powder rather than sustained-release behavior. The API granules are first milled to a D50 between 75 µm and 150 µm and blended with dextrose monohydrate, citric acid, and a low-foaming wetting agent. The target pH of the reconstituted drinking water is 4.5–5.5 to optimize dissolution and to reduce microbial proliferation in the distribution line. For a final drinking water concentration of 50 mg/L active, an API granule assay of 85.0 wt% active requires 58.8 mg of granules per liter. In a typical dosing pump set at 1.0% stock solution delivery, the stock solution is prepared at 5.0 g/L active, meaning the finished powder must deliver 5.0 g active per 100 g of finished powder. The API granule input for a 25 kg batch is therefore 1.47 kg if the final powder contains 5.0% w/w active; exact input is corrected for the granule assay and moisture content at the time of dispensing.

The milled API fraction is mixed with 10 kg of dextrose carrier in a twin-shell blender for 20 min at 25 rpm, then geometrically diluted into the remaining carrier. The moisture content of the finished powder is held below 2.0% w/w by Karl Fischer titration per USP <921>, and the powder is filled into foil-lined sachets under 30% RH to prevent caking. In-process homogeneity is verified by thief sampling at 10 positions; the active content RSD must be below 4.0% before release. Microbial limits follow USP <61>/<62> and Ph. Eur. 2.6.12/2.6.13; dispersion is assessed by a 5 min stirring test in hard water at 10 °C, with no visible agglomerates larger than 150 µm. Stability is conducted under VICH GL5. Terminal products are 100 g and 1 kg foil pouches, plus 25 kg HDPE drums for large farm systems.

When Oral Solutions Require pH Adjustment and Co-Solvent Selection

Oral solution manufacture from the granule feedstock is selected when the finished product must pass through a drench gun, oral syringe, or automated proportioner without clogging; the granule matrix is therefore either fully dissolved or reduced to a sub-sievable suspension. The main processing conflict is between the pH-dependent solubility of the active marker compound and the preservative efficacy of the selected antimicrobial system. If the solution pH is shifted above 6.8 to accelerate dissolution, the degradation rate of the active may increase and the antimicrobial effectiveness of potassium sorbate decreases; if pH drops below 4.0, the granule matrix may release insoluble cellulose fragments that block in-line filters. For a 10 mg/mL oral solution, an API granule assay of 85.0 wt% with 2.5% w/w moisture requires 11.76 g/L on an anhydrous basis and approximately 12.05 g/L as-is. The dosing correction is performed gravimetrically in a jacketed vessel, and the final volume is adjusted after HPLC assay to avoid overage accumulation in multi-dose packs.

The extraction vessel is operated at 35 ± 3 °C with a high-shear mixer at 1,500 rpm for 10 min. pH is adjusted with 0.1 N citric acid or sodium hydroxide to 5.5–6.5, and the preservative is added after the solution is cooled to 20–25 °C to minimize evaporative loss. The finished liquid is passed through a 100 µm nylon in-line strainer before filling into amber PET bottles with metering pumps. pH is controlled by USP <791>, antimicrobial effectiveness by USP <51>, and microbial limits by USP <61>/<62> for nonsterile liquids. Stability follows VICH GL5 and the packaging compatibility data required under Regulation (EU) 2019/6. Terminal product types are oral drench solutions in 1 L and 5 L HDPE jerry cans, and companion animal oral solutions in 50 mL metered-dose bottles.

Medicated feed premix production with Wuwei Changqing Granules is primarily a geometric dilution and carry-over control operation, because the API granule input represents a very small mass fraction of the finished feed and must be distributed homogeneously enough to avoid subtherapeutic or supratherapeutic intakes in group-housed animals. Regulatory compliance is anchored to Regulation (EU) 2019/4 for the manufacture and use of medicated feed, Regulation (EU) 2019/6 for the underlying veterinary medicinal product, and 21 CFR 225 for facilities exporting Type A medicated articles to the United States. At a target complete-feed concentration of 100 mg/kg active, a Type B premix is formulated at 20 g/kg active. If the API granule assay is 85.0 wt%, the required granule input is 23.5 g/kg premix. For a 25 kg Type B premix bag, that corresponds to 587.5 g API granules per batch. The resulting 25 kg bag is then incorporated at 0.5% into complete feed, delivering approximately 100 mg/kg active to the final ration.

The API granules are pre-dried to below 4.0% w/w moisture and pre-blended with 10 kg of corn cob or rice hull carrier in a ribbon blender at 20 rpm for 10 min; the premix is then geometrically diluted in a 500 kg double-ribbon mixer for 15 min. Cross-contamination is managed by dedicated lines, validated cleaning, and post-flush sampling for active residues; the limit is set in the registration dossier, and an RSD below 5.0% is required for 10-point premix thief sampling. Homogeneity testing follows the registration-specific method and uses HPLC assay with a standard curve bracketing 50–150% of the premix label. Terminal products are Type B premix bags for veterinary feed mills and Type C medicated feed mixes for on-farm use, labeled with withdrawal periods and batch numbers.

Oral Direct-Dose Granules and Paste Vehicles Require Narrow Particle-Size Retention to Preserve Dose Uniformity

Direct oral granules and paste vehicles based on the API granules are manufactured with minimal dilution to preserve the free-flowing granule structure and to limit dust generation during single-dose sachet filling. The critical processing demand is retention of the 150–850 µm particle band; if the sub-150 µm fines fraction exceeds 15% w/w, sachet filling machines drift toward overfill compensation and content uniformity suffers, while granules above 850 µm can obstruct the nozzle of oral dosing syringes. For a 1 g single-dose sachet containing 200 mg active, an API granule assay of 85.0 wt% requires 235.3 mg of API granules per sachet, or 23.5 wt% of the finished granule matrix. If the assay is 78.0 wt%, the input increases to 256.4 mg, or 25.6 wt%. The remainder is a low-dust lactose monohydrate and a palatability carrier; no additional wet granulation is used unless the sachet product is intended for direct sprinkle-to-feed administration with adhereability requirements.

Dry mixing is performed in a 200 L V-blender at 15 rpm for 15 min; the blend is then filled into preformed sachets at 20–25 °C and 30% RH to prevent moisture uptake. In-process sachet weight checks are taken every 15 min; the fill weight RSD is maintained below 1.8%. For paste formulations, the milled API granules are dispersed into a non-aqueous vehicle in a planetary mixer at 25 rpm, and the dispersion is passed through a 150 µm strainer before filling into dosing syringes. Uniformity is tested by USP <905>, moisture by USP <921> or USP <731>, and powder flow by USP <1174>. The packaging configuration is justified by VICH GL3 stability; labels include species-specific dosing tables. Terminal products are single-dose sachets, multidose HDPE jars with calibrated dosing scoops, and equine/companion animal oral paste syringes.